Medivation (NASDAQ: MDVN) is a biopharmaceutical company focused on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule in phase-III development for the treatment of castration-resistant prostate cancer. Medivation has established collaboration with Astellas for the development, manufacture, and commercialization of MDV3100 for the treatment of prostate cancer. For more information visit the company’s Web site at: www.medivation.com

William Blair & Company is a global investment banking and asset management firm committed to building enduring relationships with clients and providing expertise and solutions to meet their evolving needs. An independent and employee-owned firm, William Blair is based in Chicago, and has office locations in 10 cities, including London, New York, Shanghai, and Zurich. For more information on William Blair & Company, visit www.williamblair.com

Let us hear your thoughts below: